Showing results (11-20 of 186) with videos related to
Sort By:
Pageof 19
Cancer|January 26, 2011
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriersLarissa J Lee, Brian Alexander, Stuart J Schnitt, et al.Nature Reviews. Clinical Oncology|June 15, 2016
Counselling framework for moderate-penetrance cancer-susceptibility mutationsNadine Tung, Susan M Domchek, Zsofia Stadler, et al.Breast Cancer Research and Treatment|May 20, 2014
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancersNadine Tung, Elizabeth Gaughan, Michele R Hacker, et al.Pancreas|April 5, 2017
Chronic Pancreatitis-Like Change in BRCA2 Mutation CarriersMeir Mizrahi, Jennifer F Tseng, Daniel Wong, et al.Annals of Surgical Oncology|October 1, 2010
Does neoadjuvant bevacizumab increase surgical complications in breast surgery?M Golshan, J E Garber, R Gelman, et al.Breast Cancer Research : BCR|July 13, 2018
Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assayNeelam V Desai, Vanda Torous, Joel Parker, et al.Cancer Medicine|November 10, 2023
"Clinical trials are space travel": Factors of psychological response to recurrence among oncologists enrolling patients in treatment optimization trialsNicole Lynn Henderson, Courtney Andrews, Stacey A Ingram, et al.Gynecologic Oncology|July 7, 2009
Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriersDanielle Vicus, Barry Rosen, Jan Lubinski, et al.Menopause (New York, N.Y.)|August 16, 2020
Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriersJavier Mejia-Gomez, Jacek Gronwald, Leigha Senter, et al.International Journal of Cancer|March 27, 2023
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trialElżbieta Senkus, Suzette Delaloge, Susan M Domchek, et al.Pageof 19